Telitacicept is the world’s first and first-in-class recombinant B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) dual-target novel fusion protein product for injection independently developed by RemeGen. A total of eight of its indications in the field of autoimmune diseases are in commercialization or late-stage clinical trials. Among them, the indication for systemic lupus erythematosus (SLE) was approved for domestic sale in March 2021, and entered into the National Reimbursement Drug List (NRDL) at the end of the same year. Due to the characteristics of new target, new structure, and new mechanism, the invention patent of the drug has been authorized by China, the US, Europe, etc. The drug has received major scientific and technological support from the country’s “Significant New Drugs Creation” during the “Eleventh Five-Year Plan”, “Twelfth Five-Year Plan” and “Thirteenth Five-Year Plan.”
Disitamab Vedotin is China’s first original antibody drug conjugate (ADC) developed by RemeGen. It is the first Chinese ADC drug to be dually recognized as a breakthrough therapy by the FDA of US and NMPA of China. Its gastric cancer and urothelial cancer indications were approved for marketing by NMPA of China in June 2021, and December 2021, respectively, and entered into the National Reimbursement Drug List in January 2022 and January 2023 respectively. In August, 2021, Seagen, the internationally renowned biopharmaceutical company has obtained an exclusive global (excluding Asia Pacific) licensing agreement for the drug, with an upfront payment and milestone payments of up to 2.6 billion US dollars as well as sales royalties ranging from high single digit to more than 15%. Its transaction volume set a new record for overseas licensing of a single product by a Chinese pharmaceutical company.
Currently, the company’s product pipeline has dozens of innovative drugs in the R&D and commercialization stages. In addition to two world-class new drugs, Telitacicept and Disitamab Vedotin, another dual-target VEGF/FGF innovative fusion protein product, RC28, with the potential to be the First-in-class has entered Phase 3 clinical study in the field of ophthalmic treatments. Four drugs are in Phase 1/2 clinical studies, and many drugs are in the IND preparation stage.
STAR Market stock code:
荣昌生物:688331.SHHKEX stock code:
荣昌生物:09995.HK07 2024.10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
25 2024.09
2024 Interim Report
05 2024.09
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
26 2024.08
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO 2023 ANNUAL REPORT
16 2024.08
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
16 2024.08
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
07 2024.05
Monthly Returns Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
26 2024.04
[Annual Report] 2023 ANNUAL REPORT
08 2024.04
Monthly Returns (Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
08 2024.04
Monthly Returns Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
27 2024.03
[Final Results] ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
05 2023.12
Monthly Returns Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023